Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

Rhea-AI Summary

Theravance Biopharma (TBPH) will announce its fourth quarter and full-year 2022 financial results on February 27, 2023, after market close. A conference call and webcast are scheduled for 5:00 PM ET on the same day, allowing investors to gain insights into the company's performance. Interested parties can participate by pre-registering online. The company is known for its FDA-approved drug, YUPELRI, aimed at treating COPD and continues to focus on developing new therapies for unmet medical needs.

Positive

• Upcoming financial results may indicate growth potential.
• Strong focus on unmet patient needs through internal pipeline development.

Negative

• None.

DUBLIN, Feb. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Presentations and Events.

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through March 29, 2023.

About Theravance Biopharma

Theravance Biopharma, Inc.'s overarching purpose and goal as a biopharmaceutical company is focused on delivering Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant unmet patient needs.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023-301751428.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma report its Q4 and full year 2022 financial results?

Theravance Biopharma will report its Q4 and full year 2022 financial results on February 27, 2023.

What time is the Theravance Biopharma conference call scheduled?

The conference call is scheduled for 5:00 PM ET on February 27, 2023.

Where can I find the Theravance Biopharma financial results webcast?

The financial results webcast can be accessed on Theravance Biopharma's website under the Investors section.